Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
A Japanese health ministry panel on May 29 decided to designate the JN.1 strains of the novel coronavirus to be used as the COVID-19 vaccine antigen for its first national immunization program (NIP) to run in the upcoming 2024/2025 fall-winter…
To read the full story
Related Article
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
September 3, 2024
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
- Japan’s Fall-Winter COVID Vaccinations Likely to Start from October
July 23, 2024
- Moderna Files Updated Spikevax for JN.1 Strain in Japan
June 11, 2024
- Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
June 10, 2024
REGULATORY
- LDP Project Team Flags Drug Pricing as Key to Investment
March 19, 2026
- Japan Sets Up Radiopharma Discovery Hub in Fukushima, Targets Rare Cancers
March 18, 2026
- MHLW Seeks Industry Survey on Petroleum-Linked Products amid Iran Crisis
March 18, 2026
- MHLW Orders Label Revisions for Antiepileptics and Other Drugs
March 18, 2026
- MHLW Panel OKs Draft Criteria for “Specified Medical Technologies”
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…